WO2009085817A1 - Solutions de revêtement comprenant des segments de copolymères séquencés tensioactifs - Google Patents

Solutions de revêtement comprenant des segments de copolymères séquencés tensioactifs Download PDF

Info

Publication number
WO2009085817A1
WO2009085817A1 PCT/US2008/087152 US2008087152W WO2009085817A1 WO 2009085817 A1 WO2009085817 A1 WO 2009085817A1 US 2008087152 W US2008087152 W US 2008087152W WO 2009085817 A1 WO2009085817 A1 WO 2009085817A1
Authority
WO
WIPO (PCT)
Prior art keywords
medical device
hydrophilic
block copolymer
surface active
methacrylate
Prior art date
Application number
PCT/US2008/087152
Other languages
English (en)
Inventor
Jeffrey G. Linhardt
Devon A. Shipp
Jay Friedrich Kunzler
Original Assignee
Bausch & Lomb Incorporated
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US12/335,794 external-priority patent/US20090169716A1/en
Application filed by Bausch & Lomb Incorporated filed Critical Bausch & Lomb Incorporated
Priority to EP08867921A priority Critical patent/EP2231208A1/fr
Publication of WO2009085817A1 publication Critical patent/WO2009085817A1/fr

Links

Classifications

    • G—PHYSICS
    • G02—OPTICS
    • G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
    • G02B1/00—Optical elements characterised by the material of which they are made; Optical coatings for optical elements
    • G02B1/04—Optical elements characterised by the material of which they are made; Optical coatings for optical elements made of organic materials, e.g. plastics
    • G02B1/041—Lenses
    • G02B1/043—Contact lenses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/28—Materials for coating prostheses
    • A61L27/34—Macromolecular materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/08—Materials for coatings
    • A61L31/10—Macromolecular materials
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
    • C08J7/04—Coating
    • C08J7/0427—Coating with only one layer of a composition containing a polymer binder
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J7/00—Chemical treatment or coating of shaped articles made of macromolecular substances
    • C08J7/04—Coating
    • C08J7/056—Forming hydrophilic coatings
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09D—COATING COMPOSITIONS, e.g. PAINTS, VARNISHES OR LACQUERS; FILLING PASTES; CHEMICAL PAINT OR INK REMOVERS; INKS; CORRECTING FLUIDS; WOODSTAINS; PASTES OR SOLIDS FOR COLOURING OR PRINTING; USE OF MATERIALS THEREFOR
    • C09D153/00—Coating compositions based on block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Coating compositions based on derivatives of such polymers
    • C09D153/005—Modified block copolymers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2333/00—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers
    • C08J2333/04—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters
    • C08J2333/14—Characterised by the use of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and only one being terminated by only one carboxyl radical, or of salts, anhydrides, esters, amides, imides, or nitriles thereof; Derivatives of such polymers esters of esters containing halogen, nitrogen, sulfur, or oxygen atoms in addition to the carboxy oxygen
    • C08J2333/16—Homopolymers or copolymers of esters containing halogen atoms
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2383/00—Characterised by the use of macromolecular compounds obtained by reactions forming in the main chain of the macromolecule a linkage containing silicon with or without sulfur, nitrogen, oxygen, or carbon only; Derivatives of such polymers
    • C08J2383/10—Block- or graft-copolymers containing polysiloxane sequences
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08J—WORKING-UP; GENERAL PROCESSES OF COMPOUNDING; AFTER-TREATMENT NOT COVERED BY SUBCLASSES C08B, C08C, C08F, C08G or C08H
    • C08J2453/00—Characterised by the use of block copolymers containing at least one sequence of a polymer obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives of such polymers

Definitions

  • This invention relates to coating solutions comprising a new class of tailored polymers useful as surface coatings for ophthalmic devices.
  • These polymers can be specifically tailored using controlled radical polymerization processes and contain a number of functional domains.
  • Controlled radical polymerization allows the facile synthesis of segmented block copolymers with tunable chemical composition that, as a result, show different chemical properties than those prepared via conventional free radical polymerization.
  • Surface active segmented block copolymers show good surface properties when associated with substrates.
  • Medical devices such as ophthalmic lenses are made from a wide variety of materials.
  • materials are broadly categorized into conventional hydrogels or silicone hydrogels.
  • silicone-containing materials silicone hydrogels
  • These materials can vary greatly in water content.
  • silicone materials tend to be relatively hydrophobic, non-wettable, and have a high affinity for lipids.
  • Methods to modify the surface of silicone devices by increasing their hydrophilicity and improving their biocompatibility are of great importance.
  • US Pat. No. 6,958, 169 discloses providing a medical device formed from a monomer mixture comprising a hydrophilic device-forming monomer including a copolymerizable group and an electron donating moiety, and a second device-forming monomer including a copolymerizable group and a surface active functional group; and, contacting a surface of the medical device with a wetting agent including a proton donating moiety reactive with the functional group provided by the second lens-forming monomer and that complexes with the electron donating moiety provided by the hydrophilic lens-forming monomer.
  • US Pat. No. 6,858,310 discloses a method of modifying the surface of a medical device to increase its biocompatibility or hydrophilicity by coating the device with a removable hydrophilic polymer by means of reaction between reactive functionalities on the hydrophilic polymer with functionalities that are complementary on or near the surface of the medical device.
  • US Pat. No. 6,599,559 discloses a method of modifying the surface of a medical device to increase its biocompatibility or hydrophilicity by coating the device with a removable hydrophilic polymer by means of reaction between reactive functionalities on the hydrophilic polymer which functionalities are complementary to reactive functionalities on or near the surface of the medical device.
  • US Pat. No. 6,428,839 discloses a method for improving the wettability of a medical device, comprising the steps of: (a) providing a medical device formed from a monomer mixture comprising a hydrophilic monomer and a silicone-containing monomer, wherein said medical device has not been subjected to a surface oxidation treatment; (b) contacting a surface of the medical device with a solution comprising a proton-donating wetting agent, whereby the wetting agent forms a complex with the hydrophilic monomer on the surface of the medical device in the absence of a surface oxidation treatment step and without the addition of a coupling agent.
  • copolymers are currently made using conventional free radical polymerization techniques with the structure of the polymer being completely random or controlled by the reactivity ratios of the respective monomers.
  • controlled free radical polymerization techniques one is able to assemble copolymers in a controlled fashion and, in turn, they show completely different solution and coating properties than copolymers prepared using conventional free radical polymerization techniques.
  • Controlled free radical polymerization can be conducted by a variety of methods, such as ATRP (atom transfer radical polymerization) and RAFT (Reversible addition- fragmentation chain transfer polymerization).
  • block copolymer surfactants that can function as antifoaming agents, wetting agents, dispersants, thickeners, and emulsifiers.
  • One such surfactant class is the Pluronic® and Tetronic® block copolymers based on ethylene oxide and propylene oxide, available from BASF.
  • Another class of surfactants is the Silwet® and Silsoft® block copolymers based on ethylene oxide and siloxane blocks, available from GE silicones. These block copolymers and a variety of others rely on ring opening polymerization methods to produce the blocks.
  • block copolymers can now be prepared from a wide variety of vinyl based monomers. This opens up the toolbox for polymer chemists to synthesize countless number of block copolymer compositions.
  • surfactants there is a lot of chemical diversity in the selection of both the hydrophobic moieties and the hydrophilic moieties.
  • Surfactants or "surface active agents” lower the surface tension of water or other liquids and concentrate at the surface of the liquid.
  • Surfactants have a common structural feature in which one portion of the surfactant molecule is highly polar or even ionic (hydrophilic or water loving) and the other portion is largely non-polar (hydrophobic or water fearing). The relationship of these two structural parts of the molecule with respect to each other controls the properties of the surfactant.
  • This particular invention is related to the synthesis and preparation of specifically tailored block copolymer surfactants where both the lengths of the individual blocks, the chemical composition, and the sequence distribution are carefully controlled and the affinity of these surfactants for specific substrates can be guided by the "like prefers like" principle.
  • fluorocarbons interact with higher affinity to other fluorine- containing materials, as well as silicone containing blocks will interact with higher affinity to silicone containing materials.
  • a block copolymer surfactant is prepared via RAFT polymerization that contains a hydrophilic block (NVP or DMA), and a fluorine containing hydrophobic block (perfluoroacrylate), where the surfactant is used to treat a fluorine containing substrate (i.e.
  • a block copolymer surfactant is prepared via RAFT polymerization that contains a hydrophilic block (NVP or DMA), and a silicone containing hydrophobic block (TRIS-VC or Ml -MCR-C 12), where the surfactant is used to treat a silicone containing substrate (i.e. silicone hydrogel or a silicone elastomer).
  • RAFT polymerization that contains a hydrophilic block (NVP or DMA), and a silicone containing hydrophobic block (TRIS-VC or Ml -MCR-C 12), where the surfactant is used to treat a silicone containing substrate (i.e. silicone hydrogel or a silicone elastomer).
  • a block copolymer surfactant is prepared via RAPT polymerization that contains a hydrophilic block (NVP or DMA), and a hydrocarbon containing hydrophobic block (Hexyl methacrylate or lauryl methacrylate), where the surfactant is used to treat a hydrocarbon based substrate (i.e. polyethylene or polypropylene).
  • a hydrocarbon based substrate i.e. polyethylene or polypropylene.
  • a method of forming a surface modified medical device comprising providing a medical device having at least one surface; providing a surface modifying agent comprising a surface active segmented block copolymer; and contacting the at least one surface of the medical device with the surface modifying agent to form a surface modified medical device.
  • a surface modified medical device comprising a medical device and a surface active segmented block copolymer comprising a hydrophobic unit block comprising vinylically unsaturated polymerizable monomers and a hydrophilic block comprising vinylically unsaturated polymerizable monomers applied to the surface of the medical device.
  • the invention relates generally to coating solutions comprising surface active segmented block copolymers for forming coatings in the manufacture of medical devices.
  • suitable devices include of heart valves, intraocular lenses, intraocular lens inserter, contact lenses, intrauterine devices, vessel substitutes, artificial ureters, vascular stents, phakic intraocular lenses, aphakic intraocular lenses, corneal implants, catheters, implants, endoscopic instruments, artificial breast tissue and the like.
  • Ri is the reactive residue of a moiety capable of acting as an initiator for Atom Transfer Radical Polymerization
  • A is a hydrophobic unit block
  • B is a hydrophilic unit block
  • m is 1 to 10,000
  • n is 1 to 10,000
  • p and q are natural numbers
  • X is a halogen capping group of the initiator for Atom Transfer Radical Polymerization. It should be noted that there are many processes for the post polymerization removal or transformation of the halogen capping group of an initiator for Atom Transfer Radical Polymerization which are known to one of ordinary skill in the art.
  • polymers prepared using ATRP according to the invention herein would include those where X is a halogen capping group of the initiator for Atom Transfer Radical Polymerization and those polymers that have undergone post polymerization removal or transformation of the halogen capping group of an initiator for Atom Transfer Radical Polymerization (i.e., derivatized reaction product).
  • the polymers which contain halogen end-groups can be utilized in a host of traditional alkyl halide organic reactions.
  • the addition of tributyltin hydride to the polymeric alkyl halide in the presence of a radical source (AIBN, or Cu(I) complex) leads to a saturated hydrogen-terminated polymer.
  • polymers with allyl end groups can be prepared.
  • the terminal halogen can also be displaced by nucleophilic substitution, free-radical chemistry, or electrophilic addition catalyzed by Lewis acids to yield a wide variety of telechelic derivatives, such as alkenes, alkynes, alcohols, thiols, alkanes, azides, amines, phosphoniums, or epoxy groups, to mention a few.
  • RAFT Reversible addition-fragmentation chain transfer polymerization
  • Ri is a radical forming residue of a RAFT agent or free radical initiator
  • A is a hydrophobic unit block
  • B is a hydrophilic unit block
  • m is 1 to 10,000
  • n is 1 to 10,000
  • p and q are natural numbers
  • R 2 is a thio carbonyl thio fragment of the chain transfer agent.
  • RAFT agents based upon thio carbonyl thio chemistry are well known to those of ordinary skill in the art and would include, for example, xanthates, trithiocarbonates and dithio esters.
  • polymers prepared using RAFT agent according to the invention herein would include those where R 2 is a thio carbonyl thio fragment of the chain transfer agent and those polymers that have undergone post polymerization removal or transformation of the thio carbonyl thio fragment of the chain transfer agent (i.e., a derivatized reaction product).
  • R 2 is a thio carbonyl thio fragment of the chain transfer agent
  • polymers that have undergone post polymerization removal or transformation of the thio carbonyl thio fragment of the chain transfer agent i.e., a derivatized reaction product.
  • One example of such a transformation is the use of free radical reducing agents to replace the thio carbonyl thio group with hydrogen.
  • thermolysis of the end group or conversion of the thio carbonyl thio groups to thiol groups by aminolysis include thermolysis of the end group or conversion of the thio carbonyl thio groups to thiol groups by aminolysis.
  • a wide variety of telechelic derivatives can be prepared, such as alkenes, alkynes, alcohols, thiols, alkanes, azides, amines, phosphoniums, or epoxy groups, to mention a few.
  • Surface active segmented block copolymers prepared through reversible addition-fragmentation chain transfer polymerization (“RAFT”) methods in accordance with the invention herein have the following generic formula (III):
  • Rl is a radical forming residue of a RAFT agent or free radical initiator
  • A is a hydrophobic unit block
  • B is a hydrophilic unit block
  • m is 1 to 10,000
  • n is 1 to 10,000
  • p and q are natural numbers
  • R2 is a thio carbonyl group.
  • the order of the block units is not critical and the surface active segmented block copolymer can contain more than two blocks. Therefore the surface active segmented block copolymers can be multiblock copolymers and include repetition of one or more blocks.
  • the nonlimiting representations below each of which is intended to fall within generic formula I, II and III:
  • FIG 1 is a schematic example of atom-transfer radical polymerization (ATRP) used to make a segmented block copolymer in which there is an oligomeric block of the hydrophobic unit at one end of the polymer followed by a large hydrophilic block;
  • Figure 2 is the structural formula of various monomers which may be used to provide the hydrophobic unit of the segmented block copolymers of the invention herein;
  • Figure 3 is a reaction schematic showing how RAFT polymerization can be used to polymerize block copolymers with surface active domains.
  • the present invention relates generally to coating solutions comprising surface active segmented block copolymers.
  • Compositions comprising the surface active segmented block copolymers are useful in providing surface bound coatings in the manufacture of medical devices.
  • the present invention relates to medical devices surface coated with surface active segmented block copolymers.
  • surface as used to describe surface coating is not to be limited to meaning "at least one complete surface”. Surface coverage does not have to be even or complete to be effective for surface functionality.
  • the surface active segmented block copolymers of the present invention are useful as coatings for biocompatible materials including both soft and rigid materials commonly used for ophthalmic lenses, including contact lenses.
  • a method of forming a surface modified medical device comprising providing a medical device having at least one surface; providing a surface modifying agent comprising a surface active segmented block copolymer; and contacting the at least one surface of the medical device with the surface modifying agent to form a surface modified medical device.
  • a surface modified medical device comprising a medical device; and a surface active segmented block copolymer comprising a hydrophobic unit block and a hydrophilic block applied to the surface of the medical device.
  • the invention relates generally to coating solutions comprising surface active segmented block copolymers for forming coatings in the manufacture of medical devices.
  • suitable devices include of heart valves, intraocular lenses, intraocular lens inserter, contact lenses, intrauterine devices, vessel substitutes, artificial ureters, vascular stents, phakic intraocular lenses, aphakic intraocular lenses, corneal implants, catheters, implants, endoscopic instruments, artificial breast tissue and the like.
  • Ri is the reactive residue of a moiety capable of acting as an initiator for Atom Transfer Radical Polymerization
  • A is a hydrophobic unit block
  • B is a hydrophilic unit block
  • m is 1 to 10,000
  • n is 1 to 10,000
  • p and q are natural numbers
  • X is a halogen capping group of the initiator for Atom Transfer Radical Polymerization. It should be noted that there are many processes for the post polymerization removal or transformation of the halogen capping group of an initiator for Atom Transfer Radical Polymerization which are known to one of ordinary skill in the art.
  • polymers prepared using ATRP according to the invention herein would include those where X is a halogen capping group of the initiator for Atom Transfer Radical Polymerization and those polymers that have undergone post polymerization removal or transformation of the halogen capping group of an initiator for Atom Transfer Radical Polymerization (i.e., derivatized reaction product).
  • the polymers which contain halogen end-groups can be utilized in a host of traditional alkyl halide organic reactions.
  • the addition of tributyltin hydride to the polymeric alkyl halide in the presence of a radical source (AIBN, or Cu(I) complex) leads to a saturated hydrogen-terminated polymer.
  • polymers with allyl end groups can be prepared.
  • the terminal halogen can also be displaced by nucleophilic substitution, free-radical chemistry, or electrophilic addition catalyzed by Lewis acids to yield a wide variety of telechelic derivatives, such as alkenes, alkynes, alcohols, thiols, alkanes, azides, amines, phosphoniums, or epoxy groups, to mention a few.
  • RAFT Reversible addition-fragmentation chain transfer polymerization
  • Ri-KA n Jp-KB) 1 Jq-R 2 (II)
  • Ri is a radical forming residue of a RAFT agent or free radical initiator
  • A is a hydrophobic unit block
  • B is a hydrophilic unit block
  • m is 1 to 10,000
  • n is 1 to 10,000
  • p and q are natural numbers
  • R 2 is a thio carbonyl thio fragment of the chain transfer agent with the proviso that when A is an ionic block, B will be a nonionic block.
  • polymers prepared using RAFT agent according to the invention herein would include those where R 2 is a thio carbonyl thio fragment of the chain transfer agent and those polymers that have undergone post polymerization removal or transformation of the thio carbonyl thio fragment of the chain transfer agent (i.e., a derivatized reaction product).
  • R 2 is a thio carbonyl thio fragment of the chain transfer agent
  • a transformation is the use of free radical reducing agents to replace the thio carbonyl thio group with hydrogen.
  • Others include thermolysis of the end group or conversion of the thio carbonyl thio groups to thiol groups by aminolysis.
  • a wide variety of telechelic derivatives can be prepared, such as alkenes, alkynes, alcohols, thiols,
  • RAFT reversible addition- fragmentation chain transfer polymerization
  • the order of the block units is not critical and the surface active segmented block copolymer can contain more than two blocks. Therefore the surface active segmented block copolymers can be multiblock copolymers and include repetition of one or more blocks.
  • the nonlimiting representations below each of which is intended to fall within generic formula I, II and III:
  • the present invention provides materials useful for surface modifying contact lenses and like medical devices through the use of surface active functionality. Although only contact lenses will be referred to hereinafter for purposes of simplicity, such reference is not intended to be limiting since the subject method is suitable for surface modification of other medical devices such as phakic and aphakic intraocular lenses and corneal implants as well as contact lenses.
  • the preferred surface active segmented block copolymers in the present invention are selected based on the polymeric material to be coated.
  • the surface active segmented block copolymer comprises a hydrophobic unit block.
  • the hydrophobic unit block can be made of vinylically unsaturated polymerizable monomers.
  • Examples of hydrophobic vinylically unsaturated polymerizable monomers would include alkyl acrylates such as hexyl methacrylate and lauryl methacrylate, fluoroacrylates such as octofluoropentamethacrylate and 3,3,4,4,5,5,6,6,7,7,8,8- tridecafluorooctyl methacrylate (TDFM) and polysiloxanylalkyl (meth)acrylic monomers such as TRIS-VC and Ml -MCR-C 12.
  • alkyl acrylates such as hexyl methacrylate and lauryl methacrylate
  • fluoroacrylates such as octofluoropentamethacrylate and 3,3,4,4,5,5,6,6,7,7,8,8- tridecafluoroocty
  • the hydrophobic unit block can be varied and is selected based upon the intended use of the surface active segmented block copolymers. That is, the hydrophobic unit block of the surface active segmented block copolymers is selected to provide a composition that is complementary with the surface of the device.
  • hydrophobic unit monomer of the block copolymer is determined by the surface of the device.
  • a monomer containing fluoroalkyl substituents i.e. octafluoropentyl methacrylate
  • silicone containing monomers i.e. TRIS-methacrylate or TRIS-VC
  • TRIS-VC silicone containing monomers
  • R can consist of alkyl, fluoroalkyl, siloxy, or branched silicone.
  • Non-limiting examples would include methacryloxypropyl tris(trimethyl- siloxy)silane or tris(trimethylsiloxy)silylpropyl methacrylate, 3-(trimethylsilyl)propyl vinyl carbonate; 3-(vinyloxycarbonylthio)propyl-[tris(trimethylsiloxy)silane]; 3-[tris(tri- methylsiloxy)silyl] propyl vinyl carbamate; 3-[tris(trimethylsiloxy)silyl] propyl allyl carbamate; 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbonate; hexyl methacrylate, dodecyl methacrylate, lauryl methacrylate, hexyl vinyl carbamate, hexyl vinyl carbonate, octafluoropentamethacrylate, and octafluoropenta vinyl carbamate.
  • the hydrophobic unit block of the surface active segmented block copolymers is oligomeric or polymeric and is sized to provide suitable association with the surface of the medical device to be coated. Therefore the variable m of formula I, II or III can be between 1 and about 1000, preferably between 1 and about 100, most preferably between 1 and about 30.
  • the surface active segmented block copolymers of the invention herein will also contain hydrophilic domain(s) showing good surface properties when the block copolymer is coated onto the substrates.
  • the hydrophilic domain(s) can be made of vinylically unsaturated polymerizable monomers such as, HEMA, glycerol methacrylate, methacrylic acid (“MAA”), acrylic acid (“AA”), methacrylamide, acrylamide, N,N'-dimethylmethacrylamide, or N,N'- dimethylacrylamide; copolymers thereof; hydrophilic prepolymers, such as ethylenically unsaturated poly(alkylene oxide)s, cyclic lactams such as N-vinyl-2-pyrrolidone (“NVP”), or derivatives thereof.
  • VEP N-vinyl-2-pyrrolidone
  • Hydrophilic monomers can be nonionic monomers, such as 2-hydroxyethyl methacrylate (“HEMA”), 2-hydroxyethyl acrylate (“HEA”), 2-(2-ethoxyethoxy)ethyl (meth)acrylate, glyceryl (meth)acrylate, poly(ethylene glycol (meth)acrylate), tetrahydrofurfuryl (meth)acrylate, (meth)acrylamide, N,N'- dimethylmethacrylamide, N,N'-dimethylacrylamide("DMA”), N-vinyl-2-pyrrolidone (or other N- vinyl lactams), N- vinyl acetamide, and combinations thereof.
  • HEMA 2-hydroxyethyl methacrylate
  • HOA 2-hydroxyethyl acrylate
  • glyceryl (meth)acrylate poly(ethylene glycol (meth)acrylate), tetrahydr
  • hydrophilic monomers are the vinyl carbonate and vinyl carbamate monomers disclosed in U.S. Patent 5,070,215, and the hydrophilic oxazolone monomers disclosed in U.S. Patent 4,910,277. The contents of these patents are incorporated herein by reference.
  • the hydrophilic monomer also can be an anionic monomer, such as 2- methacryloyloxyethylsulfonate salts.
  • Substituted anionic hydrophilic monomers such as from acrylic and methacrylic acid, can also be utilized wherein the substituted group can be removed by a facile chemical process.
  • Non-limiting examples of such substituted anionic hydrophilic monomers include trimethylsilyl esters of (meth)acrylic acid, which are hydrolyzed to regenerate an anionic carboxyl group.
  • the hydrophilic monomer also can be a cationic monomer selected from the group consisting of 3- methacryIamidopropyl-N,N,N-trimethyammonium salts, 2-methacryloyloxyethyl- N,N,N-trimethylammonium salts, and amine-containing monomers, such as 3- methacrylamidopropyl-N,N-dimethyl amine.
  • Other suitable hydrophilic monomers will be apparent to one skilled in the art.
  • the hydrophilic monomer block will be sized to provide the desirable surface coating property of the surface active segmented block copolymer.
  • the size of the hydrophilic oligomeric or polymeric block may vary depending upon the substrate to be coated and the intended use. Therefore the variable n of formula I, II or III can be between 1 and about 10000, preferably between about 10 and about 1000, and more preferably between about 20 and about 300.
  • Atom-transfer radical polymerization can be used to prepare segmented block copolymers in which the molecular weight of each of the blocks and the entire polymer can be precisely controlled.
  • atom-transfer radical polymerization can be used to make a surface active segmented block copolymer in which there is a block of the hydrophobic unit at one end of the polymer followed by a large hydrophilic block.
  • the order of addition of the monomer comprising the hydrophobic unit domain and the monomer comprising the hydrophilic domain is not critical. A large number of monomers are available for the assembly of polymers (For example, see Figure 2).
  • the surface active segmented block copolymers of the invention herein are useful in providing coatings for substrates.
  • substrate materials useful with the present invention are taught in U.S. Patents 5,908,906 to K ⁇ nzler et al.; 5,714,557 to K ⁇ nzler et al.; 5,710,302 to K ⁇ nzler et al.; 5,708,094 to Lai et al.; 5,616,757 to Bambury et al.; 5,610,252 to Bambury et al.; 5,512,205 to Lai; 5,449,729 to Lai; 5,387,662 to K ⁇ nzler et al.; 5,310,779 to Lai and 6,891 ,010 to K ⁇ nzler et al.; which patents are incorporated by reference as if set forth at length herein.
  • the present invention contemplates the use of surface active segmented block copolymers with medical devices including both "hard” and “soft” contact lenses.
  • the invention is applicable to a wide variety of materials.
  • Hydrogels in general are a well-known class of materials that comprise hydrated, cross-linked polymeric systems containing water in an equilibrium state. Silicon containing hydrogels generally have water content greater than about 5 weight percent and more commonly between about 10 to about 80 weight percent. Such materials are usually prepared by polymerizing a mixture containing at least one silicon containing monomer and at least one hydrophilic monomer.
  • either the silicon containing monomer or the hydrophilic monomer functions as a crosslinking agent (a crosslinker being defined as a monomer having multiple polymerizable functionalities) or a separate crosslinker may be employed.
  • a crosslinker being defined as a monomer having multiple polymerizable functionalities
  • a separate crosslinker may be employed.
  • Applicable silicon containing monomeric units for use in the formation of silicon containing hydrogels are well known in the art and numerous examples are provided in U.S. Patent Nos. 4,136,250; 4,153,641 ; 4,740,533; 5,034,461 ; 5,070,215; 5,260,000; 5,310,779; and 5,358,995.
  • Examples of applicable silicon-containing monomeric units include bulky polysiloxanylalkyl (meth)acrylic monomers.
  • An example of bulky polysiloxanylalkyl (meth)acrylic monomers are represented by the following Formula IV: (IV) wherein:
  • X denotes -O- or -NR-; each Ri independently denotes hydrogen or methyl; each R 2 independently denotes a lower alkyl radical, phenyl radical or a group represented by n .
  • each RV independently denotes a lower alkyl or phenyl radical; and h is 1 to 10.
  • Some preferred bulky monomers are methacryloxypropyl tris(trimethyl-siloxy)silane or tris(trimethylsiloxy)silylpropyl methacrylate, sometimes referred to as TRIS.
  • silicon containing vinyl carbonate or vinyl carbamate monomers such as: 1 ,3-bis[4- vinyloxycarbonyloxy)butyl]tetramethyl-disiloxane; 3-(trimethylsilyl)propyl vinyl carbonate; 3-(vinyloxycarbonylthio)propyl-[tris(trimethylsiloxy)silane]; 3-[tris(tri- methylsiloxy)silyl] propyl vinyl carbamate; 3-[tris(trimethylsiloxy)silyl] propyl allyl carbamate; 3-[tris(trimethylsiloxy)silyl]propyl vinyl carbonate; t- butyldimethylsiloxyethyl vinyl carbonate; trimethylsilylethyl vinyl carbonate; and trimethylsilylmethyl vinyl carbonate.
  • An example of silicon-containing vinyl carbonate or vinyl carbamate monomers are represented by Formula V:
  • Y' denotes -O-, -S- or -NH-;
  • R denotes a silicon containing organic radical
  • R 3 denotes hydrogen or methyl
  • d is 1 , 2, 3 or 4
  • q is 0 or 1.
  • Suitable silicon containing organic radicals R ⁇ i include the following: -(CH 2 V Si[(CH2) m 'CH 3 ]3 ;
  • R 4 denotes
  • R 5 denotes an alkyl radical or a fluoroalkyl radical having 1 to 6 carbon atoms; e is 1 to 200; n' is 1 , 2, 3 or 4; and m' is 0, 1, 2, 3, 4 or 5.
  • silicon-containing monomers includes polyurethane- polysiloxane macromonomers (also sometimes referred to as prepolymers), which may have hard-soft-hard blocks like traditional urethane elastomers. They may be end- capped with a hydrophilic monomer such as HEMA.
  • a hydrophilic monomer such as HEMA.
  • Examples of such silicon containing urethanes are disclosed in a variety of publications, including Lai, Yu-Chin, "The Role of Bulky Polysiloxanylalkyl Methacrylates in Polyurethane-Polysiloxane Hydrogels, " Journal of Applied Polymer Science, Vol. 60, 1 193-1 199 (1996).
  • PCT Published Application No. WO 96/31792 discloses examples of such monomers, which disclosure is hereby incorporated by reference in its entirety.
  • Further examples of silicon containing urethane monomers are represented by Formulae VII and VIII:
  • D denotes an alkyl diradical, an alkyl cycloalkyl diradical, a cycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 6 to 30 carbon atoms;
  • G denotes an alkyl diradical, a cycloalkyl diradical, an alkyl cycloalkyl diradical, an aryl diradical or an alkylaryl diradical having 1 to 40 carbon atoms and which may contain ether, thio or amine linkages in the main chain;
  • * denotes a urethane or ureido linkage; a is at least 1 ;
  • A denotes a divalent polymeric radical of Formula IX:
  • each R s independently denotes an alkyl or fluoro-substituted alkyl group having 1 to 10 carbon atoms which may contain ether linkages between carbon atoms; m' is at least 1 ; and p is a number which provides a moiety weight of 400 to 10,000; each of E and E' independently denotes a polymerizable unsaturated organic radical represented by Formula X:
  • R ⁇ is hydrogen or methyl
  • R 7 is hydrogen, an alkyl radical having 1 to 6 carbon atoms, or a -CO-Y-R 9 radical wherein Y is -O-, -S- or -NH-;
  • Rg is a divalent alkylene radical having 1 to 10 carbon atoms
  • R 9 is a alkyl radical having 1 to 12 carbon atoms;
  • X denotes -CO- or -OCO-;
  • Z denotes -O- or -NH-;
  • Ar denotes an aromatic radical having 6 to 30 carbon atoms; w is 0 to 6; x is 0 or 1 ; y is 0 or 1 ; and z is 0 or 1.
  • m is at least 1 and is preferably 3 or 4
  • a is at least 1 and preferably is 1
  • p is a number which provides a moiety weight of 400 to 10,000 and is preferably at least 30
  • Rio is a diradical of a diisocyanate after removal of the isocyanate group, such as the diradical of isophorone diisocyanate
  • each E" is a group represented by:
  • a preferred silicon containing hydrogel material comprises (in the bulk monomer mixture that is copolymerized) 5 to 50 percent, preferably 10 to 25 percent, by weight of one or more silicon containing macromonomers, 5 to 75 percent, preferably 30 to 60 percent, by weight of one or more polysiloxanylalkyl (meth)acrylic monomers, and 10 to 50 percent, preferably 20 to 40 percent, by weight of a hydrophilic monomer.
  • the silicon containing macromonomer is a poly(organosiloxane) capped with an unsaturated group at two or more ends of the molecule.
  • the silane macromonomer is a silicon-containing vinyl carbonate or vinyl carbamate or a polyurethane-polysiloxane having one or more hard-soft-hard blocks and end-capped with a hydrophilic monomer.
  • Suitable hydrophilic monomers form hydrogels, such as silicon-containing hydrogel materials useful in the present invention.
  • useful monomers include amides such as dimethylacrylamide, dimethylmethacrylamide, cyclic lactams such as n-vinyl-2-pyrrolidone and poly(alkene glycols) functionalized with polymerizable groups.
  • useful functionalized poly(alkene glycols) include poly(diethylene glycols) of varying chain length containing monomethacrylate or dimethacrylate end caps.
  • the poly(alkene glycol) polymer contains at least two alkene glycol monomeric units.
  • Still further examples are the hydrophilic vinyl carbonate or vinyl carbamate monomers disclosed in U.S. Patent Nos. 5,070,215, and the hydrophilic oxazolone monomers disclosed in U.S. Patent No. 4,910,277.
  • Other suitable hydrophilic monomers will be apparent to one skilled in the art.
  • the monomer mix may, further as necessary and within limits not to impair the purpose and effect of the present invention, comprise various additives such as antioxidant, coloring agent, ultraviolet absorber and lubricant.
  • the monomer mix may be prepared by using, according to the end-use and the like of the resulting shaped polymer articles, one or at least two of the above comonomers and oligomers and, when occasions demand, one or more crosslinking agents.
  • the monomer mix is suitably prepared from one or more of the silicon compounds, e.g. siloxanyl (mefh)acrylate, siloxanyl (meth)acrylamide and silicon containing oligomers, to obtain contact lenses with high oxygen permeability.
  • the silicon compounds e.g. siloxanyl (mefh)acrylate, siloxanyl (meth)acrylamide and silicon containing oligomers
  • the monomer mix may include additional constituents such as crosslinking agents, internal wetting agents, hydrophilic monomelic units, toughening agents, and other constituents as is well known in the art.
  • the monomer mix may include toughening agents, preferably in quantities of less than about 80 weight percent e.g. from about 5 to about 80 weight percent, and more typically from about 20 to about 60 weight percent. Examples of suitable toughening agents are described in U.S. Pat. No. 4,327,203.
  • These agents include cycloalkyl acrylates or methacrylates, such as: methyl acrylate and methacrylate, /-butylcyclohexyl methacrylate, isopropylcyclopentyl acrylate, t- pentylcycloheptyl methacrylate, /-butylcyclohexyl acrylate, isohexylcyclopentyl acrylate and methylisopentyl cyclooctyl acrylate.
  • suitable toughening agents are described in U.S. Pat. No. 4,355, 147.
  • This reference describes polycyclic acrylates or methacrylates such as: isobornyl acrylate and methacrylate, dicyclopentadienyl acrylate and methacrylate, adamantyl acrylate and methacrylate, and isopinocamphyl acrylate and methacrylate. Further examples of toughening agents are provided in U.S. Pat. No. 5,270,418. This reference describes branched alkyl hydroxyl cycloalkyl acrylates, methacrylates, acrylamides and methacrylamides.
  • Representative examples include: 4-/-butyl-2-hydroxycyclohexyl methacrylate (TBE); 4-f-butyl-2- hydroxycyclopentyl methacrylate; methacryloxyamino-4-f-butyl-2-hydroxycyclohexane; 6-isopentyl-3-hydroxycyclohexyl methacrylate; and methacryloxyamino-2-isohexyl-5- hydroxycyclopentane.
  • TBE 4-/-butyl-2-hydroxycyclohexyl methacrylate
  • 4-f-butyl-2- hydroxycyclopentyl methacrylate methacryloxyamino-4-f-butyl-2-hydroxycyclohexane
  • 6-isopentyl-3-hydroxycyclohexyl methacrylate 6-isopentyl-3-hydroxycyclohexyl methacrylate
  • methacryloxyamino-2-isohexyl-5- hydroxycyclopentane methacryloxy
  • surface structure and composition determine many of the physical properties and ultimate uses of solid materials. Characteristics such as wetting, friction, and adhesion or lubricity are largely influenced by surface characteristics. The alteration of surface characteristics is of special significance in biotechnical applications where biocompatibility is of particular concern. Thus, it is desired to provide a silicon containing hydrogel contact lens with an optically clear, hydrophilic surface film that will not only exhibit improved wettability, but which will generally allow the use of a silicon containing hydrogel contact lens in the human eye for extended period of time.
  • a silicon containing hydrogel lens for extended wear, it be further desirable to provide an improved silicon-containing hydrogel contact lens with an optically clear surface film that will not only exhibit improved lipid and microbial behavior, but which will generally allow the use of a silicon-containing hydrogel contact lens in the human eye for an extended period of time.
  • Such a surface treated lens would be comfortable to wear in actual use and allow for the extended wear of the lens without irritation or other adverse effects to the cornea.
  • these surface enhancing coatings may be desirable to apply these surface enhancing coatings to implantable medical devices such as intraocular lens materials to reduce the attachment of lens epithelial cells to the implanted device and to reduce friction as the intraocular lens passes through an inserter into the eye. It may also be desirable to apply these surface enhancing coatings to surgical instruments such as intraocular lens inserters and endoscopic instruments.
  • Methods of coating the substrate would include dip coating of the substrate into a solution containing the surface modifying agent.
  • the solution containing the surface modifying agent may contain substantially the surface modifying agent in solvent or may contain other materials such as cleaning and extracting materials.
  • Other methods could include spray coating the device with the surface modifying agent.
  • the substrate and the other surface modifying agent may be subjected to autoclave conditions.
  • the substrate and the surface modifying agent may be autoclaved in the packaging material that will contain the coated substrate. Once the contact between the substrate and the surface modifying agent has occurred, the remaining surface modifying agent could be substantially removed and packaging solution would be added to the substrate packaging material. Sealing and other processing steps would then proceed as they usually do.
  • the surface modifying agent could be retained in the substrate packaging material during storage and shipping of the substrate device to the end user.
  • the treated lenses are allowed to cool for a minimum of 3 hours, then removed from the vials and rinsed at least three times with deionized water.
  • the rinsed lenses are then placed into new vials containing 4 ml of borate buffered saline (phosphate for samples undergoing bacterial adhesion testing) and autoclaved for one 30- minute cycle for sterilization.
  • contact lenses such as those comprising other hydrogel materials can be treated with coating polymers, as disclosed above.
  • Pure VisionTM contact lenses comprising Balafilcon A hydrogel material disclosed in U.S. Patent 5,260,000, which is incorporated herein by reference, are surface-treated with a coating polymer as disclosed above.
  • Pur VisionTM contact lenses are available from Bausch and Lomb Incorporated, Rochester, New York.
  • Pure VisionTM contact lenses are first treated with a plasma discharge generated in a chamber containing air.
  • a packaging solution for surface treatment comprised segmented block poly(TRIS-b-DMA) is added to a blister package before the lens is placed in and sealed around the perimeter of the receptacle with lidstock, The blister containing the lens is then autoclaved for one 30-minute cycle for sterilization.
  • a fluoro-silicone hydrogel contact lenses are packaged in a container that includes a receptacle portion to hold the contact lens and a sterile packaging solution comprising a segmented block poly(OFPMA-b-DMA).
  • a receptacle portion to hold the contact lens
  • a sterile packaging solution comprising a segmented block poly(OFPMA-b-DMA).
  • Examples of the container are conventional contact lens blister packages.
  • This receptacle, containing the contact lens immersed in the solution is hermetically sealed, for example, by sealing lidstock on the package over the receptacle. For example, the lidstock is sealed around a perimeter of the receptacle.
  • the solution and the contact lens are sterilized while sealed in the package receptacle.
  • sterilization techniques include subjecting the solution and the contact lens to thermal energy, microwave radiation, gamma radiation or ultraviolet radiation.
  • a specific example involves heating the solution and the contact lens, while sealed in the package container, to a temperature of at least 100 0 C, more preferably at least 120 0 C, such as by autoclaving.
  • the packaging solution is an aqueous solution that includes the surface active segmented block copolymer, preferably in an amount of 0.02 to 5.0 weight percent, based on total weight of the packaging solution.
  • the specific amount of surface active segmented block copolymer will vary depending on the substrate and the copolymer, but generally, the surface active segmented block copolymer will be present in an amount within this range.
  • the packaging solutions preferably have a pH of about 6.0 to 8.0, more preferably about 6.5 to 7.8, and most preferably 6.7 to 7.7.
  • Suitable buffers include monoethanolamine, diethanolamine, triethanolamine, tromethamine (tris(hydroxymethyl)aminomethane, Tris), Bis-Tris, Bis-Tris Propane, borate, citrate, phosphate, bicarbonate, amino acids, and mixtures thereof.
  • specific buffering agents include boric acid, sodium borate, potassium citrate, citric acid, Bis- Tris, Bis-Tris Propane, and sodium bicarbonate. When present, buffers will generally be used in amounts ranging from about 0.05 to 2.5 percent by weight, and preferably from 0.1 to 1.5 percent by weight.
  • the packaging solutions may further include a tonicity adjusting agent, optionally in the form of a buffering agent, for providing an isotonic or near-isotonic solution having an osmolality of about 200 to 400 m ⁇ sm/kg, more preferably about 250 to 350 mOsm/kg.
  • a tonicity adjusting agent optionally in the form of a buffering agent, for providing an isotonic or near-isotonic solution having an osmolality of about 200 to 400 m ⁇ sm/kg, more preferably about 250 to 350 mOsm/kg.
  • suitable tonicity adjusting agents include sodium and potassium chloride, dextrose, glycerin, calcium and magnesium chloride. When present, these agents will generally be used in amounts ranging from about 0.01 to 2.5 weight percent and preferably from about 0.2 to about 1.5 weight percent.
  • packaging solutions may include an antimicrobial agent, but it is preferred that the solutions lack such an agent.
  • the surface active segmented block copolymers useful in certain embodiments of the present invention may be prepared according to syntheses well known in the art and according to the methods disclosed in the following examples. Surface modification of contact lenses using one or more surface modifying agents in accordance with the present invention is described in still greater detail in the examples that follow.
  • Example B Synthesis of NVP-b-TRIS-VC (Two Step)
  • AIBN (23.2 mgs; 1.41 x i ⁇ "4 mol) was added to a 100 mL Schlenk flask equipped with a magnetic stirring bar. To the flask was added 147 mgs (7.05 x 10 '4 ) of ethyl- ⁇ -(O- ethylxanthyl) propionate (EEXP) dissolved in a small amount of dioxane. Dioxane (15 ml) and N-vinylpyrrolidone (NVP) [15 ml; 0.141 mol] were added to the Schlenk flask, which was then sealed and purged with N 2 for 30 minutes. The flask was placed in an oil bath (6O 0 C) for 24 hours.
  • NDP N-vinylpyrrolidone
  • the second block (TRIS-VC) was added to the PVP MacroRAFT agent in a second reaction.
  • Ten grams of PVP MacroRAFT agent (approx. 1.67 x 10 "3 mol) was added to a 100 mL Schlenk flask along with 20 mL of 1,4-dioxane and a stir bar.
  • 14.127-g (3.3 x 10 "2 mol) of TRIS-VC and 54.8 mgs of AIBN (3.33 x 10 "4 mol) were then added to the flask which was sealed and purged with N 2 for 60 minutes.
  • the reaction was then heated for 1 1 hours in a 6O 0 C oil bath.
  • the reaction mixture was dissolved in methanol (creating a dispersion).
  • Dialysis tubes (Spectra/por 6, MWCO 3500) were filled with the solution and submerged in IL of methanol solvent with slow stirring. The solvent was changed after 4h, I9.5h, and 41.5h. The tubes were removed at 48h and the methanol was removed with a rotary evaporator. The resulting polymer was dried in a vacuum oven.
  • Both the PVP MacroRAFT agent and the block copolymer of NVP and TRIS- VC were characterized by proton NMR (CDC13) and GPC.
  • the NMR spectrum of the block copolymer shows peaks present from the TRIS-VC block at 0.0 ppm and 0.3 ppm and distinct peaks from the PVP segments between 1.0-2.5 ppm and 3.0-4.0 ppm. From the integrations it is estimated that the ratio of NVP:TRIS-VC is approximated at 29: 1 by
  • NVP 10 ml; 0.09 mol.
  • Xanthate 0.094 g, 4.5x10-4 mol.
  • AIBN 15 mg, 9.0x10-5 mol.
  • 1,4 dioxane 10 ml
  • TRIS-VC 3.81 g, 8.99x10-3 mol.
  • AIBN 15 mg, 9.0x10-5 mol.
  • 1 ,4-dioxane 4 ml
  • the second block may actually be a statistical copolymerization of the TRIS-VC and any remaining NVP that had not been polymerized at the time of the TRIS-VC addition.
  • the second "block" is therefore compositionally heterogeneous.
  • a polymerization that yields a statistical copolymerization or compositionally heterogeneous block as the second block would also be considered to be a reactive segmented block copolymer according to the invention herein.
  • TDFM 3,3,4,4,5,5,6,6,7,7,8,8-tridecafluorooctyl methacrylate
  • both the first precipitate and the block copolymer of DMA and hydrophobic methacrylate were characterized by proton NMR (CDC13) and GPC (DMF as eluent).
  • the GPC chromatograms all show a shift in the elution peaks to shorter times (higher MW) after the addition of the hydrophobic methacrylate blocks.
  • the NMR spectra of the block copolymers for samples -152, -154, and -156 above show a broad peak at around 4.5 ppm corresponding to the methylene group adjacent to the methacrylate of 3,3,4,4,5,5,6,6,7,7,8,8-tridecafluorooctyl methacrylate (TDFM).
  • the NMR of the block copolymers for samples -153, -155, and -157 show peaks for the -CH3 group (0.8 ppm) and -CH2- groups (1.3 ppm) of the alkyl chain of lauryl methacrylate
  • Example E Synthesis of a matrix of GMA-b-DMA Copolymers where the MW of each of the blocks is varied
  • Reaction 2748-1 14 is described below as an example of the procedure used.
  • DMA N,N-Dimethylacrylamide
  • Both the first precipitate and the block copolymer of DMA and GMA were characterized by proton NMR (CDC13) and GPC.
  • the GPC shows a shift in the elution peak to shorter times (higher MW) after the addition of the GMA block.
  • the NMR spectra of the block copolymer show peaks for the glycidol methacrylate contributions at 3.7 ppm and 4.3 ppm.
  • GPC data for these polymers using DMF as an eluent are shown below, using both PMMA standards and PVP standards as calibrants. Although the trends in MW are the same, PMMA standards show MW' s much closer to the theoretically expected value for polyDMA.
  • Example F Packaging a lens with a surfactant
  • aqueous packaging solution containing 1% by weight of the silicone- containing surfactant NVP-b-TRIS-VC of Example 1 dissolved in a borate buffered saline at a pH of 7.2 is placed in a polypropylene blister package.
  • a balafilcon A contact lens is immersed in the aqueous packaging solution in the polypropylene blister package.
  • the package is sealed with foil lidstock and then autoclaved for 30 minutes at 121°C.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • General Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Wood Science & Technology (AREA)
  • Materials Engineering (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Graft Or Block Polymers (AREA)
  • Materials For Medical Uses (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Macromonomer-Based Addition Polymer (AREA)
  • Eyeglasses (AREA)
  • Coating Of Shaped Articles Made Of Macromolecular Substances (AREA)

Abstract

Cette invention concerne le traitement de surface d'un dispositif, ledit traitement de surface comprenant le placement de segments de copolymères séquencés tensioactifs sur la surface du substrat. La présente invention concerne également un dispositif médical à surface modifiée comprenant, à titre d'exemples, les lentilles de contact, les lentilles intraoculaires, les endoprothèses vasculaires, les lentilles intraoculaires phakiques, les lentilles intraoculaires aphakiques, les implants cornéens, les cathéters, les implants, et autres, comprenant une surface préparée selon ce procédé.
PCT/US2008/087152 2007-12-27 2008-12-17 Solutions de revêtement comprenant des segments de copolymères séquencés tensioactifs WO2009085817A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP08867921A EP2231208A1 (fr) 2007-12-27 2008-12-17 Solutions de revêtement comprenant des segments de copolymères séquencés tensioactifs

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US1684307P 2007-12-27 2007-12-27
US61/016,843 2007-12-27
US12/335,794 US20090169716A1 (en) 2007-12-27 2008-12-16 Coating solutions comprising surface active segmented block copolymers
US12/335,794 2008-12-16

Publications (1)

Publication Number Publication Date
WO2009085817A1 true WO2009085817A1 (fr) 2009-07-09

Family

ID=40521758

Family Applications (2)

Application Number Title Priority Date Filing Date
PCT/US2008/086990 WO2009085756A1 (fr) 2007-12-27 2008-12-16 Solutions de revêtement comprenant des segments de copolymères séquencés interactifs
PCT/US2008/087152 WO2009085817A1 (fr) 2007-12-27 2008-12-17 Solutions de revêtement comprenant des segments de copolymères séquencés tensioactifs

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PCT/US2008/086990 WO2009085756A1 (fr) 2007-12-27 2008-12-16 Solutions de revêtement comprenant des segments de copolymères séquencés interactifs

Country Status (4)

Country Link
EP (2) EP2231207A1 (fr)
JP (1) JP2011508908A (fr)
CN (1) CN101977638A (fr)
WO (2) WO2009085756A1 (fr)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104193923A (zh) * 2014-10-13 2014-12-10 陕西省石油化工研究设计院 一种疏水/疏油氟硅三嵌段聚合物及其制备方法
US20160058919A1 (en) * 2014-09-02 2016-03-03 Sumitomo Rubber Industries, Ltd. Metal medical device
CN110431201A (zh) * 2017-02-07 2019-11-08 昆塔波尔公司 用于改性金属氧化物表面的单层聚合物涂层
US10647829B2 (en) 2013-06-20 2020-05-12 Sumitomo Rubber Industries, Ltd. Surface modification method and surface modification body
US10759918B2 (en) 2015-08-03 2020-09-01 Sumitomo Rubber Industries, Ltd. Surface modification method and surface-modified elastic body

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8454689B2 (en) * 2008-12-30 2013-06-04 Bausch & Lomb Incorporated Brush copolymers
HUE027398T2 (en) * 2009-05-22 2016-10-28 Novartis Ag Proteolymers containing siloxane having actinically crosslinkable
US20100315588A1 (en) * 2009-06-16 2010-12-16 Bausch & Lomb Incorporated Biomedical devices
US9522980B2 (en) 2010-05-06 2016-12-20 Johnson & Johnson Vision Care, Inc. Non-reactive, hydrophilic polymers having terminal siloxanes and methods for making and using the same
US9170349B2 (en) 2011-05-04 2015-10-27 Johnson & Johnson Vision Care, Inc. Medical devices having homogeneous charge density and methods for making same
JP5439551B2 (ja) 2011-08-15 2014-03-12 一般財団法人川村理化学研究所 ブロック共重合体の塗膜
US20130323295A1 (en) * 2011-12-08 2013-12-05 Johnson & Johnson Vision Care, Inc. Monomer systems with dispersed silicone-based engineered particles
CA2874718A1 (fr) * 2012-05-25 2013-11-28 Johnson & Johnson Vision Care, Inc. Polymeres et materiaux nanogels, et leurs procedes de preparation et d'utilisation
US9244196B2 (en) 2012-05-25 2016-01-26 Johnson & Johnson Vision Care, Inc. Polymers and nanogel materials and methods for making and using the same
US10073192B2 (en) 2012-05-25 2018-09-11 Johnson & Johnson Vision Care, Inc. Polymers and nanogel materials and methods for making and using the same
US9486311B2 (en) 2013-02-14 2016-11-08 Shifamed Holdings, Llc Hydrophilic AIOL with bonding
US10195018B2 (en) 2013-03-21 2019-02-05 Shifamed Holdings, Llc Accommodating intraocular lens
AU2014236688B2 (en) 2013-03-21 2019-07-25 Shifamed Holdings, Llc Accommodating intraocular lens
WO2016033217A1 (fr) 2014-08-26 2016-03-03 Shifamed Holdings, Llc Lentille intraoculaire adaptative
US11141263B2 (en) 2015-11-18 2021-10-12 Shifamed Holdings, Llc Multi-piece accommodating intraocular lens
US10350056B2 (en) 2016-12-23 2019-07-16 Shifamed Holdings, Llc Multi-piece accommodating intraocular lenses and methods for making and using same
CA3064855A1 (fr) 2017-05-30 2018-12-06 Shifamed Holdings, Llc Traitements de surface pour lentilles intraoculaires d'accommodation et methodes et dispositifs associes
WO2018227014A1 (fr) 2017-06-07 2018-12-13 Shifamed Holdings, Llc Lentilles intraoculaires à puissance optique réglable
WO2019150260A1 (fr) * 2018-01-30 2019-08-08 Novartis Ag Lentilles de contact pourvues d'un revêtement lubrifié
JP2022508521A (ja) * 2018-10-01 2022-01-19 マイクロベンション インコーポレイテッド 医療機器
CA3125780A1 (fr) * 2019-01-29 2020-08-06 Bausch & Lomb Incorporated Solution de conditionnement pour des lentilles de contact
JP7329956B2 (ja) * 2019-04-25 2023-08-21 大塚化学株式会社 Ｎ－アルケニルラクタム系ブロック共重合体を含有する重合生成物および重合生成物の製造方法
EP4119587A4 (fr) * 2020-03-12 2024-03-20 Toray Industries Agent de revêtement et matériau médical l'utilisant

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162905A1 (en) * 2002-02-27 2003-08-28 Benz Michael Eric AnB block copolymers containing poly (vinyl pyrrolidone) units, medical devices, and methods
US20050107531A1 (en) * 2003-11-14 2005-05-19 Claude Charles D. Block copolymers of acrylates and methacrylates with fluoroalkenes
WO2005068571A1 (fr) * 2004-01-15 2005-07-28 Menicon Co., Ltd. Agent de revetement applique a la surface de lentille oculaire
US20070026043A1 (en) * 2003-11-20 2007-02-01 Angiotech International Ag Medical devices combined with diblock copolymer compositions
WO2007024500A1 (fr) * 2005-08-25 2007-03-01 Medtronic Vascular, Inc. Compositions de copolymeres sequences derives d'une polymerisation radiale commandee destinees a des revetements de dispositifs medicaux
US20070155907A1 (en) * 2005-12-30 2007-07-05 Zhao Jonathon Z Biologically active block copolymers
US20070154521A1 (en) * 2005-12-30 2007-07-05 Zhao Jonathon Z Tri-branched biologically active copolymer
JP2007206166A (ja) * 2006-01-31 2007-08-16 Menicon Co Ltd 眼用レンズ表面用コーティング剤およびそれにより得られる眼用レンズ
US20070264303A1 (en) * 2006-05-12 2007-11-15 Liliana Atanasoska Coating for medical devices comprising an inorganic or ceramic oxide and a therapeutic agent

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136250A (en) 1977-07-20 1979-01-23 Ciba-Geigy Corporation Polysiloxane hydrogels
US4153641A (en) 1977-07-25 1979-05-08 Bausch & Lomb Incorporated Polysiloxane composition and contact lens
US4740533A (en) 1987-07-28 1988-04-26 Ciba-Geigy Corporation Wettable, flexible, oxygen permeable, substantially non-swellable contact lens containing block copolymer polysiloxane-polyoxyalkylene backbone units, and use thereof
US4910277A (en) 1988-02-09 1990-03-20 Bambury Ronald E Hydrophilic oxygen permeable polymers
US5070215A (en) 1989-05-02 1991-12-03 Bausch & Lomb Incorporated Novel vinyl carbonate and vinyl carbamate contact lens material monomers
US5034461A (en) 1989-06-07 1991-07-23 Bausch & Lomb Incorporated Novel prepolymers useful in biomedical devices
US5310779A (en) 1991-11-05 1994-05-10 Bausch & Lomb Incorporated UV curable crosslinking agents useful in copolymerization
US5358995A (en) 1992-05-15 1994-10-25 Bausch & Lomb Incorporated Surface wettable silicone hydrogels
US5260000A (en) 1992-08-03 1993-11-09 Bausch & Lomb Incorporated Process for making silicone containing hydrogel lenses
US5321108A (en) 1993-02-12 1994-06-14 Bausch & Lomb Incorporated Fluorosilicone hydrogels
US5616757A (en) 1993-04-08 1997-04-01 Bausch & Lomb Incorporated Organosilicon-containing materials useful for biomedical devices
US5760100B1 (en) 1994-09-06 2000-11-14 Ciba Vision Corp Extended wear ophthalmic lens
DE69615393T2 (de) 1995-12-07 2002-07-04 Bausch & Lomb Monomere zur reduzierung des modulus von siloxynhydrogele
US5708094A (en) 1996-12-17 1998-01-13 Bausch & Lomb Incorporated Polybutadiene-based compositions for contact lenses
US6630243B2 (en) * 1999-05-20 2003-10-07 Bausch & Lomb Incorporated Surface treatment of silicone hydrogel contact lenses comprising hydrophilic polymer chains attached to an intermediate carbon coating
US6981010B1 (en) 2000-08-02 2005-12-27 Board Of Regents Of The University Of Nebraska System and method for generating psuedo-noise sequences
US7298344B2 (en) * 2002-05-20 2007-11-20 Raytheon Company Series fed amplified antenna reflect array
US6958169B2 (en) 2002-12-17 2005-10-25 Bausch & Lomb Incorporated Surface treatment of medical device
US7176268B2 (en) * 2003-12-05 2007-02-13 Bausch & Lomb Incorporated Prepolymers for improved surface modification of contact lenses
US7988988B2 (en) * 2005-11-21 2011-08-02 Bausch & Lomb Incorporated Contact lenses with mucin affinity
WO2007064594A2 (fr) * 2005-11-29 2007-06-07 Bausch & Lomb Incorporated Nouveaux revetements sur lentilles ophtalmique

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030162905A1 (en) * 2002-02-27 2003-08-28 Benz Michael Eric AnB block copolymers containing poly (vinyl pyrrolidone) units, medical devices, and methods
US20050107531A1 (en) * 2003-11-14 2005-05-19 Claude Charles D. Block copolymers of acrylates and methacrylates with fluoroalkenes
US20070026043A1 (en) * 2003-11-20 2007-02-01 Angiotech International Ag Medical devices combined with diblock copolymer compositions
WO2005068571A1 (fr) * 2004-01-15 2005-07-28 Menicon Co., Ltd. Agent de revetement applique a la surface de lentille oculaire
WO2007024500A1 (fr) * 2005-08-25 2007-03-01 Medtronic Vascular, Inc. Compositions de copolymeres sequences derives d'une polymerisation radiale commandee destinees a des revetements de dispositifs medicaux
US20070155907A1 (en) * 2005-12-30 2007-07-05 Zhao Jonathon Z Biologically active block copolymers
US20070154521A1 (en) * 2005-12-30 2007-07-05 Zhao Jonathon Z Tri-branched biologically active copolymer
JP2007206166A (ja) * 2006-01-31 2007-08-16 Menicon Co Ltd 眼用レンズ表面用コーティング剤およびそれにより得られる眼用レンズ
US20070264303A1 (en) * 2006-05-12 2007-11-15 Liliana Atanasoska Coating for medical devices comprising an inorganic or ceramic oxide and a therapeutic agent

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200557, Derwent World Patents Index; AN 2005-563975, XP002523684 *
DATABASE WPI Week 200776, Derwent World Patents Index; AN 2007-809281, XP002523683 *
See also references of EP2231208A1 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10647829B2 (en) 2013-06-20 2020-05-12 Sumitomo Rubber Industries, Ltd. Surface modification method and surface modification body
US20160058919A1 (en) * 2014-09-02 2016-03-03 Sumitomo Rubber Industries, Ltd. Metal medical device
US10092680B2 (en) * 2014-09-02 2018-10-09 Sumitomo Rubber Industries, Ltd. Metal medical device
CN104193923A (zh) * 2014-10-13 2014-12-10 陕西省石油化工研究设计院 一种疏水/疏油氟硅三嵌段聚合物及其制备方法
US10759918B2 (en) 2015-08-03 2020-09-01 Sumitomo Rubber Industries, Ltd. Surface modification method and surface-modified elastic body
CN110431201A (zh) * 2017-02-07 2019-11-08 昆塔波尔公司 用于改性金属氧化物表面的单层聚合物涂层

Also Published As

Publication number Publication date
JP2011508908A (ja) 2011-03-17
CN101977638A (zh) 2011-02-16
EP2231208A1 (fr) 2010-09-29
WO2009085756A1 (fr) 2009-07-09
EP2231207A1 (fr) 2010-09-29

Similar Documents

Publication Publication Date Title
US20090169716A1 (en) Coating solutions comprising surface active segmented block copolymers
EP2231208A1 (fr) Solutions de revêtement comprenant des segments de copolymères séquencés tensioactifs
EP2597113A1 (fr) Solutions de revêtement comprenant des segments de copolymères séquencés réactifs
WO2009085819A1 (fr) Copolymères séquencés segmentés à surface active
EP1572261B1 (fr) Traitement de surface d'un dispositif medical
US8454689B2 (en) Brush copolymers
EP2091585B1 (fr) Traitement de surface de dispositifs biomédicaux
EP2443482B1 (fr) Dispositifs biomédicaux, materiaux polymères et lentilles de contact les comprenant.
WO2007064594A2 (fr) Nouveaux revetements sur lentilles ophtalmique
EP2035050A2 (fr) Modification des surfaces d'articles polymères par réaction d'addition de michael
WO2009085759A1 (fr) Copolymères à blocs réactifs segmentés
WO2010078107A1 (fr) Copolymères en brosse
US20100168851A1 (en) Surface Modified Biomedical Devices
WO2007047716A2 (fr) Dispositifs medicaux a surface modifiee et leur procede de fabrication
US20070264509A1 (en) Copolymer and Medical Device with the Copolymer
US20070264503A1 (en) Polymers comprising polyhydric alcohols, medical devices modified with same, and method of making
WO2007064565A1 (fr) Procede de revetement pour materiau de lentille
EP2061818A2 (fr) Macromonomères hydrophiles comportant un groupement terminal carboxylique alpha, beta-conjugué et dispositifs médicaux les incorporant
US20090156745A1 (en) Surface modified biomedical devices

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08867921

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008867921

Country of ref document: EP